Kasabach-Merritt Syndrome

This is a serious condition that can happen in babies and young children. It involves a type of blood vessel growth called a hemangioma. This growth can block blood flow and cause the body's blood to thin out, leading to low platelet counts. This can cause bleeding problems and anemia. It's often linked to a specific type of hemangioma called Kaposiform Hemangioendothelioma.

Condition

What people with Kasabach-Merritt Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you tried Sirolimus for Kasabach-Merritt Syndrome?

NameHow it went

About Kasabach-Merritt Syndrome

What It Is

Kasabach-Merritt syndrome, more often called Kasabach-Merritt phenomenon, is a serious bleeding and clotting problem caused by a rare blood vessel tumor. Platelets (the blood cells that help form clots) and clotting proteins get trapped and used up inside the tumor, so their levels in the rest of the body fall sharply. The result is a high risk of bruising and bleeding, and it can be life-threatening without treatment. It almost always affects babies and young children. The tumor behind it is usually a kaposiform hemangioendothelioma, a rare, locally aggressive growth of blood and lymph vessels, or a closely related, milder tumor called a tufted angioma. These usually appear in the first year of life, often on the neck, armpit, groin, limbs or trunk, but some grow deep inside the chest or abdomen with nothing visible on the skin. When the phenomenon starts, the tumor typically swells quickly and turns purple, warm and painful. Despite the older name "hemangioma-thrombocytopenia syndrome," it does not develop from the common infantile hemangioma (the familiar strawberry mark), which is a different and far more common growth. Very rarely, a similar clotting problem occurs in adults with a very large liver hemangioma; that situation is managed differently.

Causes & Risk Factors

The direct cause is the tumor itself. Kaposiform hemangioendothelioma and tufted angioma contain unusual, tangled vessels that catch platelets as blood flows through them. Trapped platelets become activated, the tumor consumes fibrinogen (a key clotting protein), and the tumor can grow further as more blood collects in it. That cycle is why the platelet count can keep falling. Not every child with one of these tumors develops the phenomenon, but most children with kaposiform hemangioendothelioma do. The risk is higher when the tumor is deep and infiltrating, or when it sits behind the abdominal cavity or inside the chest. No inherited gene change has been identified as a cause, and researchers do not yet fully understand why these tumors form.

How It's Diagnosed

Diagnosis brings together what the growth looks like, blood tests and imaging. A rapidly enlarging, firm, purple swelling in an infant, together with new bruising or tiny pinpoint red spots on the skin, is the classic picture. Blood tests are essential. A complete blood count measures platelets; a normal adult count is about 150,000 to 450,000 per microliter. In this condition the count often falls to between 3,000 and 60,000, and widespread pinpoint spots tend to appear when it drops below about 10,000. Clotting tests usually show a low fibrinogen level and a high D-dimer (a fragment released when clots break down), which together show that clotting factors are being used up. Anemia (a low red blood cell count) can also occur. Doppler ultrasound, which shows blood flow, is usually the first scan, followed by MRI (magnetic resonance imaging) to map how far the tumor extends into nearby tissue. Specialists generally recommend a biopsy to confirm the tumor type and to rule out cancers that can look similar, but it is sometimes too risky while bleeding risk is high, in which case treatment is guided by the other findings.

Treatment Options

Treatment aims to stop the tumor from consuming platelets, which brings the counts back up, and then to shrink the tumor. Because these tumors are so rare, care is best coordinated through a vascular anomalies center, where hematologists, surgeons and other specialists work together. The usual first treatment is sirolimus, an oral medicine that calms abnormal blood vessel growth, combined with a corticosteroid such as prednisolone. Sirolimus is approved in the US for uses such as preventing kidney transplant rejection, so its use here is off-label but well established in specialist practice. Platelet counts often start to rise within days, and clotting tests improve over a few weeks. Sirolimus needs regular blood tests to keep its level in range, and it weakens the immune system, so infection risk is part of the trade-off; mouth sores and raised cholesterol are other common effects. Steroids are tapered once the clotting problem settles, while sirolimus is often continued for a year or more and then slowly reduced. If the tumor is pressing on the airway or another vital structure, or the response is not good enough, vincristine, a chemotherapy medicine given into a vein, is added. It usually requires a central line and can cause constipation and nerve irritation. When medicines fail, options include embolization (blocking the tumor's blood supply through a catheter) and, rarely, surgery when the tumor can be removed completely without serious harm. Supportive care is handled differently than for other low-platelet conditions. Platelet transfusions are usually avoided, because the tumor traps the new platelets, which can make it swell and worsen the count. They are reserved for active bleeding or surgery. Clotting-factor products may be given when bleeding or a procedure calls for them, and pain control matters because the swollen tumor can be very painful.

What to Expect

Once treatment takes hold, the clotting problem usually resolves and the tumor gradually shrinks, although it may not disappear completely. Early weeks often involve a hospital stay, frequent blood tests and close monitoring of the tumor's size. After that, most children continue treatment at home with regular clinic visits, sirolimus level checks and periodic MRI scans. Families often need guidance on infection precautions and vaccine timing while a child is taking immune-suppressing medicine. Outlook depends largely on how severe the clotting problem is and where the tumor sits. Tumors deep in the abdomen or chest carry higher risk, partly because they tend to be found later. The tumor can return, especially after medicine is stopped, so long-term follow-up is recommended even after things look settled. Some children are left with lasting effects such as persistent swelling (lymphedema) in an affected limb, chronic pain, stiffness, scarring or reduced function near the tumor site. Compression garments, a gentle massage technique called manual lymphatic drainage and, for scarring or leftover tissue, surgery can help.

When to Seek Help

Arrange a prompt medical assessment for any baby or young child with a firm, purple or rapidly growing skin lump, especially if it is warm or tender, rather than assuming it is an ordinary birthmark. If a baby with such a lump also has new bruising or tiny pinpoint red or purple spots, get the baby seen the same day, whether or not a tumor has been diagnosed. For a child with a known vascular tumor, contact the care team the same day if the tumor suddenly swells, darkens or becomes painful, or if new bruising or tiny pinpoint red or purple spots appear. During treatment, call the care team right away about any fever, since sirolimus and steroids lower the body's defense against infection. Call 911 if the child has trouble breathing, which can happen when a tumor presses on the airway. Go to an emergency department for bleeding that will not stop with firm pressure, or blood in vomit or stool.

Questions to Ask Your Doctor

  1. 1.What type of vascular tumor is causing this, and is a biopsy needed to confirm it?
  2. 2.Is my child being cared for by, or in contact with, a vascular anomalies center?
  3. 3.How will we know treatment is working, and how often will blood tests and scans be needed?
  4. 4.How long is treatment with sirolimus likely to last, and what precautions should we take about infections and vaccines?
  5. 5.What long-term effects should we watch for, and what support is available if they develop?

Last reviewed • Oct 2026

Educational content, not medical advice.